SkySparc Appoints Oliver Bussmann as Chairman of the Board
Appointment of industry veteran follows majority growth investment from Bregal Milestone
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm.
As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth.
Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth.
“We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Joakim Wiener, CEO of SkySparc. “His unparalleled experience in financial technology and expansive global network will play a pivotal role as we build on our growth momentum and deliver the next generation of AI-powered finance solutions.”
“I am honoured to take on the role of Chairman. With its strong market position, the OmniFi platform, and its innovative use of AI and advanced analytics, SkySparc is well placed to empower CFOs and treasurers in modernizing their financial architectures,” said Oliver Bussmann, Chairman of the Board at SkySparc. “Together with Joakim, the SkySparc team, and Bregal Milestone, I am excited to help shape SkySparc’s next chapter of global growth.”
About SkySparc
SkySparc is a leading provider of digital transformation solutions for finance and treasury organizations worldwide. Combining deep domain expertise with its proprietary platform OmniFi, SkySparc helps treasurers and CFOs globally automate processes, improve cash visibility, and gain actionable insights through AI and advanced analytics. Founded in 2002, SkySparc is trusted by leading corporates and financial institutions across Europe, North America, and Asia. For more information, visit www.skysparc.com or follow us on LinkedIn.
About Bregal Milestone
Bregal Milestone is a leading software private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading software companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognized by GrowthCap as one of the Top Private Equity Firms of 2025. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118869207/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HP Becomes Sisvel Wi-Fi 6 Pool Licensee, Ending Disputes with Wilus, Huawei and Philips18.11.2025 10:58:00 CET | Press release
HP Inc and Sisvel have concluded an agreement for the Palo Alto-based global technology leader to become a licensee of the Sisvel Wi-Fi 6 patent pool. The deal follows a mediation process ordered by Judge Rodney Gilstrap, of the US District Court for the Eastern District of Texas, as part of patent infringement litigation brought against HP by Wilus Institute of Standards and Technology, a licensor in the pool. The agreement not only ends the Wilus suit, but also actions launched against HP by other Sisvel Wi-Fi 6 pool licensors, Huawei and Philips. HP now has one-stop access to approximately 2,000 patents (245 patent families) recognised to date, through the pool’s process of independent patent evaluations, as essential to the 802.11ax Wi-Fi 6 standard. Close to 40 entities license the patents in the Sisvel Wi-Fi 6 patent pool. In addition to HP Inc, these include other recent additions such as Cisco, Netgear and Acer. “We are grateful to HP for the constructive way in which they enga
Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises18.11.2025 10:00:00 CET | Press release
Series A led by Creandum, with Elaia and Speedinvest, will accelerate the product development of GetVocal’s AI customer experience platform GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces. Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in bla
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom